Cost-effectiveness of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with highvolume, metastatic, hormone-sensitive prostate cancer
Background: Rezvilutamide, a novel androgen-receptor inhibitor with limited blood-brain barrier penetration, exhibits significant antitumour activity against highvolume, metastatic, hormone-sensitive prostate cancer (mHSPC). In this study, we aimed to compare the cost-effectiveness of rezvilutamide...
Gorde:
Egile Nagusiak: | , , , , , , |
---|---|
Formatua: | Liburua |
Argitaratua: |
Frontiers Media S.A.,
2024-01-01T00:00:00Z.
|
Gaiak: | |
Sarrera elektronikoa: | Connect to this object online. |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Internet
Connect to this object online.3rd Floor Main Library
Sailkapena: |
A1234.567 |
---|---|
Alea 1 | Eskuragarri |